secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002944
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Q1 net loss $5.5M, cash only until end-May 2025; cites need for financing
--------------------------------------------------------------------------------

- Net loss of $5.5M for Q1 2025 vs. $9.6M a year ago; EPS loss $2.61.
- Cash and restricted cash $4.7M; company expects runway only through May 2025.
- TUSCANY trial: all six patients on 40 or 80 mg TUS+VEN+AZA achieved complete remissions.
- Common shares delisted from Nasdaq effective April 2, 2025 due to equity deficiency.
- Management pursuing financing and cost cuts to extend cash runway beyond May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/0001171843-25-002944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/f8k_050825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer